ARA-290 – 10mg

Innate Repair Receptor (IRR) Activation — Selectively binds the IRR — a cell surface complex found on nerve, immune, and vascular cells — triggering localized tissue-protective and anti-inflammatory signaling without engaging EPO’s hematopoietic pathway. Neuroprotection & Nerve Regeneration — Preclinical and early clinical studies show ARA-290 may reduce neuropathic pain, support corneal nerve fiber regeneration, and promote functional recovery following peripheral nerve injury — with particular interest in diabetic and sarcoidosis-related neuropathy. Targeted Anti-inflammatory Action — Rather than broadly suppressing immunity, ARA-290 rebalances local inflammatory responses — reducing pro-inflammatory cytokines and shifting immune cells toward a tissue-repair profile, with reductions in markers like CRP observed in small trials. Safe EPO-Derived Profile — By isolating EPO’s protective domain while eliminating sequences responsible for erythropoiesis, ARA-290 avoids the cardiovascular risks of EPO therapy (hypertension, thromboembolism) while retaining its regenerative benefits, with high subcutaneous bioavailability (>85%).